Latest G-Protein Coupled Receptors Companies Update
Nov 2023: An exclusive worldwide licensing and commercialization deal has been inked by Thermo Fisher Scientific and transplant diagnostic company Verici DX to create a pre-transplant prognostic test to detect kidney rejection risk assessment. Thermo Fisher will receive the worldwide rights to commercialize the test, as well as the exclusive license to develop and market an assay for pre-transplant risk evaluation as a laboratory-developed test in its CLIA-certified laboratory in the United States, from Verici DX, based in Cardiff, U.K. The partnership's goal, according to a statement from Verici DX, is to create a test that can risk stratifying patients according to how they will probably react to a kidney transplant. This will help clinicians make more educated decisions regarding immunosuppressive therapy and post-transplant care.
Nov 2023: To broaden the range of applications for digital PCR technology, Qiagen has announced the release of new kits with its QIAcuity systems and a significant software update. These applications include cell and gene therapies, DNA and RNA quantification, and food and pharmaceutical safety. The QIAcuity Mycoplasma Quant Kit provides researchers with a precise and accurate method to identify mycoplasma contamination at every stage of the development and production of gene and cell therapies. On the other hand, researchers can measure RNA or RNA combined with DNA in a single reaction using the extremely sensitive QIAcuity OneStep Advanced EG Kit. The kit's intercalating dye technology reduces costs and simplifies method design compared to fluorescent-probe-based PCR.List of G-Protein Coupled Receptors Key companies in the market
- Thermo Fisher Scientific, Inc. (US)
- Abcam PLC (UK)
- QIAGEN (Germany)
- Promega Corporation (US)
- PerkinElmer Inc. (US)
- Enzo Life Sciences, Inc. (US)
- BD (US)
- Cisbio (Europe)
- Merck Group (Germany)
- HD Biosciences Co., Ltd (China)